A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

Recruiting

Phase 1

Phase 2

RSV/hMPV VaccineA Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

Sponsor:

GlaxoSmithKline

Code:

NCT07628049

Conditions

Respiratory Syncytial Virus Infections+Metapneumovirus

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

RSV/hMPV_V low dose vaccine

RSV/hMPV_V medium dose vaccine

RSV/hMPV_V high dose vaccine

RSV/hMPV_W low dose vaccine

RSV/hMPV_W medium dose vaccine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-11. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2026-07-08.